An islet cell transplant for type 1 diabetes transfers insulin-producing cells from a deceased donor’s pancreas into a person with difficult-to-manage diabetes. These cells may begin producing insulin, stabilize blood glucose, and reduce severe hypoglycemia.
However, this specialized type 1 diabetes cell therapy does not suit most people with the condition. Transplant centers generally consider it for carefully selected adults who experience repeated severe low blood sugar despite intensive insulin treatment, diabetes education, continuous glucose monitoring, and other advanced care.
What Is an Islet Cell Transplant for Type 1 Diabetes?
Pancreatic islets are tiny groups of cells located throughout the pancreas. They contain beta cells that monitor blood glucose and release insulin when levels rise.
In type 1 diabetes, the immune system mistakenly destroys these beta cells. Consequently, the pancreas produces little or no insulin, and the person must use insulin injections or an insulin pump.
During pancreatic islet transplantation, specialists isolate islets from a deceased donor’s pancreas. The medical team then infuses these donor islet cells into the recipient’s liver, where surviving cells may establish a blood supply and produce insulin.
How Donor Islet Cells Control Blood Sugar
Healthy beta cells continuously respond to changing glucose levels. For example, they release more insulin after a meal and reduce insulin production when glucose starts falling.
Injected insulin effectively manages type 1 diabetes, but it cannot always reproduce this precise biological response. Therefore, some people continue experiencing severe hypoglycemia or unpredictable glucose changes despite careful treatment.
A successful beta cell transplant may restore part of the body’s glucose-responsive insulin production. Although the cells do not rebuild the pancreas, they may function from their new location in the liver.
Who May Qualify for Pancreatic Islet Transplantation?
Transplant teams reserve an islet cell transplant for type 1 diabetes for adults whose condition remains dangerous despite intensive care. Eligibility requirements vary among countries, transplant centers, products, and clinical programs.
Potential candidates may have repeated severe hypoglycemia that requires another person’s assistance. They may also have hypoglycemia unawareness, major glucose fluctuations, or difficulty reaching their HbA1c target despite insulin pumps, continuous glucose monitoring, and structured diabetes education.
In the United States, the FDA approved Lantidra for certain adults who cannot approach their HbA1c target because repeated severe hypoglycemia continues despite intensive diabetes management. Therefore, doctors do not recommend this treatment when insulin therapy and available technology control diabetes successfully.
Who May Not Be Suitable for an Islet Transplant?
A transplant team must determine whether the possible benefits outweigh the risks of the infusion procedure and long-term immunosuppression. People who cannot safely take anti-rejection medicines do not qualify for this treatment.
Active infection, certain cancers, significant liver disease, serious kidney problems, blood-clotting disorders, or uncontrolled cardiovascular disease may affect eligibility. In addition, pregnancy plans and difficulty following a complex treatment schedule may influence the decision.
However, each transplant center applies specific medical criteria. An endocrinologist and transplant specialist must review the person’s diabetes history, organ function, hypoglycemia episodes, current technology, and previous treatment efforts.
How an Islet Cell Transplant for Type 1 Diabetes Works?
Preparing Donor Islet Cells
First, specialists recover a suitable pancreas from a deceased organ donor. A laboratory team then separates and purifies the pancreatic islets before checking their quality, quantity, sterility, and viability.
Meanwhile, the recipient begins an immunosuppressive treatment plan. These medicines weaken the immune response that would otherwise attack the donor islet cells.
Infusing Islet Cells Into the Liver
Next, an interventional radiologist or surgeon inserts a thin catheter into the portal vein, which carries blood to the liver. The medical team slowly delivers the islet cell suspension through this catheter.
This procedure is less invasive than a whole-pancreas transplant because surgeons do not place a complete organ inside the abdomen. Nevertheless, complications can include bleeding, liver injury, abdominal pain, increased portal pressure, and portal vein thrombosis.
Monitoring Transplanted Beta Cells
After the infusion, surviving islets settle within small liver blood vessels and begin developing a blood supply. As a result, some transplanted beta cells may start releasing insulin in response to blood glucose.
Recipients must continue insulin until their diabetes team advises otherwise. Clinicians closely monitor glucose, insulin requirements, liver function, and C-peptide, which shows whether the transplanted cells produce insulin.
Considering Additional Islet Infusions
One procedure may not deliver enough functioning islets. Therefore, some recipients need a second or third infusion to improve glucose control or regain insulin independence.
However, each additional infusion introduces further procedural and immunosuppressive risks. The transplant team reviews graft function, liver health, insulin needs, and previous complications before recommending another procedure.
Benefits of an Islet Cell Transplant for Type 1 Diabetes
The primary goal of an islet cell transplant for type 1 diabetes is to prevent severe hypoglycemia while improving glucose control. Complete insulin independence may occur, but doctors cannot guarantee that outcome.
Potential benefits include fewer severe low blood sugar episodes, improved hypoglycemia awareness, more stable glucose readings, increased time within the target range, and lower insulin requirements. Moreover, some recipients report less fear of hypoglycemia and a better diabetes-related quality of life.
Even partial graft function may provide meaningful benefits. For instance, a recipient may still use insulin but experience fewer dangerous lows and more predictable glucose levels.
Can Pancreatic Islet Transplantation Stop Insulin Treatment?
Some recipients produce enough insulin after pancreatic islet transplantation to stop injections or pump therapy for a period. In contrast, others reduce their insulin dose but continue using supplemental insulin.
In the small studies supporting FDA approval of Lantidra, 21 of 30 participants achieved insulin independence for at least one year. Eleven maintained it for one to five years, while ten exceeded five years. However, five participants never became insulin-independent.
These uncontrolled studies included highly selected adults, so their findings cannot predict an individual result. Furthermore, graft function may decline because of rejection, inflammation, medication toxicity, or gradual cell loss.
Risks of an Islet Cell Transplant for Type 1 Diabetes
An islet cell transplant for type 1 diabetes carries risks from the portal-vein infusion and long-term anti-rejection treatment. Consequently, specialists recommend it only when severe hypoglycemia presents a greater danger than transplantation.
Possible procedural complications include bleeding, liver injury, portal vein thrombosis, infection, abdominal pain, increased portal pressure, and failure of the donor cells to function. Additionally, the graft may work initially but lose function later.
Exposure to donor tissue can also cause the recipient to develop antibodies. These antibodies may complicate matching if the person needs a kidney or another organ transplant in the future.
Immunosuppressive Medicine After Islet Cell Transplantation
The recipient’s immune system recognizes donor islet cells as foreign. Therefore, recipients generally take immunosuppressive medicines for as long as the transplanted cells continue functioning.
These medicines can increase the risk of serious infections, kidney damage, high blood pressure, anemia, digestive problems, tremors, headaches, and certain cancers. They may also raise blood glucose, cholesterol, or triglyceride levels.
Moreover, some immunosuppressants may damage transplanted islets over time. A recipient should never stop anti-rejection medicine independently because sudden withdrawal can trigger rejection and destroy graft function.
Is Lantidra a Cure for Type 1 Diabetes?
Lantidra is the first FDA-approved donor pancreatic islet cellular therapy for selected adults with type 1 diabetes. Specialists administer the donor cells through a single infusion into the liver’s portal vein, although some patients may need additional infusions.
Lantidra can restore insulin production and sometimes provide insulin independence. However, it does not offer a guaranteed or permanent cure because patients require immunosuppression, graft function may decline, and some recipients continue using insulin.
Therefore, describing Lantidra as a universal cure would be inaccurate. It provides another treatment option for a small group of adults with repeated severe hypoglycemia despite intensive care.
Islet Cell Transplant vs Pancreas Transplant
Both treatments aim to restore natural insulin production, but they differ considerably. An islet transplant places isolated cells into the liver, whereas a pancreas transplant requires major surgery to place a complete donor organ in the body.
| Feature | Islet Cell Transplant | Pancreas Transplant |
| Transplanted material | Isolated pancreatic islets | Whole donor pancreas |
| Procedure | Portal-vein cell infusion | Major abdominal surgery |
| Insulin independence | Possible but less predictable | More likely after successful surgery |
| Repeat procedures | Multiple infusions may be necessary | Usually one organ transplant |
| Immunosuppression | Required | Required |
| Main limitation | Cell shortage and graft durability | Major surgical complications |
| Typical candidate | Repeated severe hypoglycemia | Serious complications, often kidney failure |
Although an islet infusion involves less surgery, it does not eliminate serious risks. A specialist transplant team must decide which treatment, if either, provides the safer option.
Evaluation Before a Beta Cell Transplant
A transplant team first confirms that severe hypoglycemia continues despite appropriate diabetes management. Specialists review continuous glucose monitor data, HbA1c results, emergency episodes, insulin delivery, glucose variability, and hypoglycemia awareness.
The evaluation may include blood tests, urine tests, kidney and liver assessments, cardiovascular testing, infection screening, cancer screening, tissue typing, and antibody testing. Furthermore, the team may assess psychological health, social support, and the person’s ability to follow long-term treatment.
The evaluation also confirms whether the person has tried suitable alternatives. Continuous glucose monitoring, automated insulin delivery, structured education, and individualized glucose targets may reduce severe hypoglycemia without transplant risks.
Recovery After an Islet Cell Transplant for Type 1 Diabetes
Following the donor islet infusion, clinicians monitor glucose closely while the cells begin functioning. Insulin requirements may change quickly, so the recipient must follow the transplant team’s dosing instructions.
Follow-up appointments may include HbA1c, C-peptide, kidney tests, liver assessments, blood counts, infection screening, and immunosuppressant level checks. In addition, clinicians monitor for bleeding, blood clots, rejection, and medication toxicity.
Even after achieving insulin independence, recipients must continue glucose monitoring and specialist follow-up. They also need to report fever, unusual fatigue, abdominal pain, bleeding, reduced urination, or other concerning symptoms promptly.
Current Availability of Islet Cell Therapy
Islet cell transplantation for type 1 diabetes remains uncommon and is available through specialized medical programs. Access depends on regulatory approval, transplant-center expertise, donor availability, medical eligibility, and healthcare or insurance policies.
Donor cells remain scarce because only a limited number of pancreases meet the requirements for islet isolation. Moreover, laboratory processing and transplantation can damage or destroy part of the recovered cells.
Long-term immunosuppression creates another major barrier. Consequently, current donor islet transplantation cannot serve as a routine treatment for everyone living with type 1 diabetes.
Stem Cell-Derived Islets and Future Treatment
Researchers are developing insulin-producing islets from stem cells to create a more dependable cell supply. Early studies suggest that these cells can produce insulin, improve glucose control, and reduce insulin requirements in selected participants.
However, stem cell-derived islet therapies remain experimental. Researchers still need to establish their long-term safety, durability, ideal dose, immune protection, and effectiveness in larger groups.
Scientists are also testing encapsulation materials and genetically modified cells that may avoid immune rejection. If successful, these approaches could eventually reduce or remove the need for lifelong immunosuppression.
When to Consult a Transplant Specialist?
A person should discuss islet cell transplantation for type 1 diabetes with an endocrinologist when severe hypoglycemia continues despite optimized insulin therapy, continuous glucose monitoring, diabetes education, and automated insulin delivery.
A specialist referral may also help when hypoglycemia unawareness causes seizures, loss of consciousness, injuries, emergency visits, or repeated dependence on another person for treatment.
However, islet transplantation does not treat an active hypoglycemic emergency. During a severe low, caregivers should follow the person’s emergency plan, administer glucagon when available, and contact emergency services when necessary.
Islet Cell Transplant for Type 1 Diabetes: Final Thoughts
An islet cell transplant for type 1 diabetes may restore glucose-responsive insulin production, prevent severe hypoglycemia, stabilize blood sugar, and sometimes provide insulin independence. Nevertheless, specialists reserve it for carefully selected adults with dangerous hypoglycemia despite intensive management.
The possible benefits require careful comparison with infusion complications, donor-cell shortages, uncertain graft durability, and long-term immunosuppression. Therefore, an experienced endocrinology and transplant team should determine whether this treatment offers an appropriate option.
FAQS
No. Islet transplantation is generally reserved for selected adults with repeated severe hypoglycemia despite intensive insulin management, diabetes education, continuous glucose monitoring, and other appropriate treatments.
Not necessarily. Some recipients achieve insulin independence, while others need less insulin or experience improved glucose stability. Transplanted cells may gradually lose function, requiring insulin again.
The portal vein provides a practical route for delivering donor islets. The cells settle in the liver’s small blood vessels, establish a blood supply, and may produce insulin.
Yes. Donor islet recipients generally require long-term immunosuppression while the cells function. These medicines prevent rejection but may cause infections, kidney damage, and other serious adverse effects.
Stem cell-derived islet therapies remain under clinical investigation. Early findings are encouraging, but researchers still need to establish long-term safety, effectiveness, durability, and protection from immune attack.
Islet cell function varies among recipients. Some grafts produce insulin for several years, while others decline sooner because of rejection, inflammation, medication toxicity, or cell loss.
Current FDA-approved donor islet therapy is intended for eligible adults. Islet cell transplantation in children remains highly limited because immunosuppression risks may outweigh the expected benefits.
Some patients achieve meaningful glucose control after one infusion, while others need a second or third transplant. Additional procedures depend on graft function, insulin requirements, and safety.
A successful islet cell transplant for type 1 diabetes may significantly reduce or prevent severe hypoglycemia by restoring glucose-responsive insulin production, even when supplemental insulin remains necessary.
If donor islet cells lose function, blood glucose may rise and insulin requirements can return. The transplant team may adjust treatment or consider another infusion when appropriate.
